

Dear Ladies & Gentlemen

We are very pleased to announce that as of July 20, 2023, all shares of Idorsia Pharmaceuticals Japan Ltd have been transferred to Sosei Group Corporation, and the company will become a wholly owned subsidiary of Sosei Group.

The company name and address will remain unchanged.

Very sincerely yours,

Satoshi Tanaka Dr. med. Sci
President & Representative Director
Idorsia Pharmaceuticals Japan Ltd.

=Sosei Group Corporation=

Headquartered in Chiyoda-ku, Tokyo, Japan, the company has a research and development facility in Cambridge, UK.

An international group of biopharmaceutical companies focused on the discovery and early development of new drug candidates derived from its proprietary StaR® and structure-based drug discovery (SBDD) technologies targeting G protein-coupled receptors (GPCRs). The company is building a broad pipeline in multiple therapeutic areas, primarily in neurological, immunological, gastrointestinal, and inflammatory diseases.

Dear Ladies & Gentlemen

We are pleased to hear that your business is prospering more and more.

We would like to take this opportunity to thank you for your continued support.

At the extraordinary general meeting of shareholders and the meeting of the Board of Directors held on July 20, the following directors were elected and assumed their respective offices.

We, the board of directors and executive officers, are determined to do our utmost for the development of the company's business to meet your expectations.

Very sincerely yours,

Satoshi Tanaka Dr. med. Sci
President & Representative Director
Idorsia Pharmaceuticals Japan Ltd.

Satoshi Tanaka	President & Representative Director
Hiroaki Tanaka	Senior Managing & Representative Director
Kazutaka Matsubara	Vice President
Hironoshin Nomura	Managing Director
Kazuhiko Yoshizumi	Managing Director
Christopher R Cargill	Director
Ming Du	Director Drug Safety
Masato Okochi	Director Finance & Accounting
Masato Miyauchi	Director
Mariko Nakafuji	Director
Kazushige Itabashi	Senior Corporate Officer Head of Legal, Licensing and Intellectual Properties
Kazuo Ishikawa	Senior Corporate Officer Head of Strategic Business Alliance
Yoshikazu Shibata	Corporate Officer Head of Medical Marketing
Shuya Takahashi	Corporate Officer Head of Medical Affairs
Norihiko Kurosawa	Corporate Officer Head of Quality Assurance
Hiroshi Kuranari	Statutory Auditor